A Phase 1 Dose-escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Veliparib (Primary) ; Carboplatin
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 11 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 20 Jan 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.